PathWhiz

PathWhiz ID	Pathway	Meta Data
PW128037 View Pathway	drug action Rivaroxaban Action Pathway Homo sapiens Rivaroxaban is an anticoagulant that inhibits coagulation factor X, typically used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Rivaroxaban is indicated for patients at high risk of DVT, PE and any other recurrent thrombotic events. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Rivaroxaban competitively inhibits free and clot-bound factor X. Coagulation factor X makes up a part of the prothrombinase complex that is responsible for the conversion of prothrombin to thrombin. Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which creates the loose meshwork that eventually forms into a blood clot. Patients should avoid herbs and supplements with anticoagulant activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba. In addition, St. John's Wort should also be avoided as it will decrease blood concentration levels of rivaroxaban. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Selena Created On: July 06, 2023 at 10:17 Last Updated: July 06, 2023 at 10:17
PW132486 View Pathway	metabolic Rivaroxaban Drug Metabolism Homo sapiens Rivaroxaban is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Rivaroxaban passes through the liver and is then excreted from the body mainly through the kidney. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: September 21, 2023 at 22:02 Last Updated: September 21, 2023 at 22:02
PW145688 View Pathway	drug action Rivaroxaban Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:23 Last Updated: October 07, 2023 at 16:23
PW128009 View Pathway	drug action Rivastigmine Action Pathway Homo sapiens Rivastigmine is a cholinesterase inhibitor used in the treatment of symptoms of dementia in Alzheimer's and Parkinson's. The drug reversible binds to and inhibits acetylcholinesterase and cholinesterase which stops the breakdown of acetylcholine which increases the concentration in the synaptic cleft. It is metabolized by the enzymes it inhibits and forms the metabolite NAP226-90. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Selena Created On: June 29, 2023 at 09:31 Last Updated: June 29, 2023 at 09:31
PW128292 View Pathway	drug action Rivastigmine Action Pathway (new) Homo sapiens Rivastigmine is a cholinesterase inhibitor used in the treatment of symptoms of dementia in Alzheimer's and Parkinson's. The drug reversible binds to and inhibits acetylcholinesterase and cholinesterase which stops the breakdown of acetylcholine which increases the concentration in the synaptic cleft. It is metabolized by the enzymes it inhibits and forms the metabolite NAP226-90. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Selena Created On: August 15, 2023 at 18:47 Last Updated: August 15, 2023 at 18:47
PW145087 View Pathway	drug action Rivastigmine Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 15:03 Last Updated: October 07, 2023 at 15:03
PW176230 View Pathway	metabolic Rivastigmine Predicted Metabolism Pathway Homo sapiens Metabolites of Rivastigmine are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: December 04, 2023 at 12:58 Last Updated: December 04, 2023 at 12:58
PW145052 View Pathway	drug action Rizatriptan Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:59 Last Updated: October 07, 2023 at 14:59
PW128616 View Pathway	drug action Rizatriptan Mechanism of Action Action Pathway Homo sapiens Rizatriptan is a triptan used to treat migraines with or without aura. Rizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Rizatriptan is not indicated for the prophylactic therapy of migraine nor the treatment of cluster headache. Rizatriptan has a weak affinity for other 5-HT1 receptor subtypes (5-HT1A, 5-HT1E, 5-HT1F) and the 5-HT7 receptor but has no significant activity at 5-HT2, 5-HT3, alpha- and beta-adrenergic, dopaminergic, histaminergic, muscarinic or benzodiazepine receptors. Rizatriptan is a selective agonist at the 5-HT1B and 5-HT1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system. It binds to these receptors with high affinity. The exact mechanism of action of rizatriptan has not been fully elucidated; however, several documented pharmacological actions of rizatriptan may contribute to its antimigraine effects. Rizatriptan causes vasoconstriction of intracranial extracerebral blood vessels, which is thought to occur primarily via 5-HT1B receptors. Rizatriptan also inhibits nociceptive neurotransmission in trigeminal pain pathways. It attenuates the release of vasoactive neuropeptides by the trigeminal nerve, which is thought to occur via neurogenic and central 5-HT1D receptors. Rizatriptan inhibited neurogenic dural vasodilation and plasma protein extravasation in animal studies. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: September 06, 2023 at 16:32 Last Updated: September 06, 2023 at 16:32
PW123685 View Pathway	metabolic RL Test Pseudomonas aeruginosa Rhamnolipids (RL) consist of a fatty acyl moiety composed of a 3-(3-hydroxyalkanoyloxy)alkaloid acid (HAA) and a sugar moiety composed of one or two rhamnose sugars. Rhamnolipids function as surfactants and virulence factors and are involved in biofilm formation and cell motility. The rhamnose sugar component is produced via the dTDP-L-rhamnose biosynthetic pathway which forms dTDP-L-rhamnose from glucose 6-phosphate (G6P) in five steps. First, glucose 6-phosphate is converted into glucose 1-phosphate (G1P) via the enzyme phosphoglucomutase (AlgC). Second, glucose 1-phosphate is converted into dTDP-D-glucose via the enzyme glucose-1-phosphate thymidylyltransferase (RmlA). Third, dTDP-D-glucose is converted into dTDP-4-dehydro-6-deoxy-D-glucose via the enzyme dTDP-glucose 4,6-dehydratase (RmlB). Fourth, dTDP-4-dehydro-6-deoxy-D-glucose is converted into dTDP-4-dehydro-L-rhamnose via the enzyme dTDP-4-dehydrorhamnose 3,5-epimerase (RmlC). Fifth, dTDP-4-dehydro-L-rhamnose is converted into dTDP-L-rhamnose via the enzyme dTDP-4-dehydrorhamnose reductase (RmlD). The HAA component is synthesized from 3-hydroxyacyl-[acyl-carrier protein] diverted from fatty acid biosynthesis via the enzyme 3-(3-hydroxydecanoyloxy)decanoate synthase (RhIA). The final step in rhamnolipid biosynthesis is the formation of the glycosidic link between the rhamnose sugar component and the HAA component. This is accomplished by two rhamnosyltransferases (RhlB and RhlC) which catalyze sequential glycosyl transfer reactions to first form mono-rhamnolipids (via RhIB) and then di-rhamnolipids (via RhIC). RHlA, RHlB, and RHlC are associated with the inner membrane. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Carin Li Created On: January 17, 2020 at 10:59 Last Updated: January 17, 2020 at 10:59